Beam Therapeutics Inc is a leading biotechnology company focused on developing precision genetic medicines using its proprietary base editing platform. The company's values center around innovation, collaboration, and commitment to improving patient lives. Beam Therapeutics is dedicated to advancing the understanding and application of base editing technology to address genetic diseases with unmet medical needs. By harnessing the potential of DNA base editing, the company aims to deliver transformative therapies that can permanently correct genetic mutations at the source. Through its cutting-edge approach and dedication to patient-centric innovation, Beam Therapeutics Inc strives to make a significant impact in the field of genetic medicine.

Beam Therapeutics Inc is primarily present in the United States.

Beam Therapeutics Inc has achieved significant milestones since its inception. These include the successful completion of their initial public offering (IPO) in 2020, raising substantial funds to support ongoing research and development activities. The company has also made advancements in its proprietary base editing technology platform, which holds great potential for treating a wide range of genetic diseases. Furthermore, Beam Therapeutics has established strategic collaborations with renowned academic institutions and biopharmaceutical companies to expedite the development and commercialization of their innovative therapies. These achievements highlight the company's dedication to revolutionizing healthcare through precise, durable, and efficient genetic medicines.

Beam Therapeutics Inc. is a biotechnology company that was founded in 2017. It specializes in developing precision genetic medicines using its proprietary base editing technology. This innovative technology allows for the precise and efficient alteration of individual base pairs within the genome. Beam Therapeutics aims to address a wide range of diseases, including genetic and rare diseases, as well as oncology indications. The company's mission is to create a new class of genetic medicines that offer long-lasting and potentially curative benefits for patients. With its dedicated focus on base editing, Beam Therapeutics is at the forefront of advancing the field of genetic medicine.

The main competitors of Beam Therapeutics Inc in the market include Editas Medicine, CRISPR Therapeutics, and Intellia Therapeutics.

Beam Therapeutics Inc is primarily active in the biotechnology industry. As a leading biotechnology company, Beam Therapeutics focuses on developing precision genetic medicines using its proprietary base editing platform. By harnessing the power of CRISPR technology, Beam Therapeutics aims to address a wide range of diseases caused by genetic mutations. With its innovative approach, extensive research, and strategic partnerships, Beam Therapeutics is at the forefront of advancements in gene editing and therapeutic solutions.

Beam Therapeutics Inc's business model revolves around developing and commercializing precision genetic medicines using its proprietary base editing technology platform. By leveraging CRISPR technology, Beam aims to correct errors at the molecular level by making precise changes to the DNA code, allowing for the treatment of a wide range of diseases. By focusing on a diverse pipeline of therapeutics across multiple disease areas, Beam Therapeutics Inc aims to transform the landscape of genetic medicine and provide innovative solutions for patients in need.

Beam Therapeutics KGV ir -6,41.

Beam Therapeutics KUV ir 50,02.

AlleAktien kvalitātes vērtējums Beam Therapeutics ir 3/10.

gaidāmā Beam Therapeutics apgrozījums ir 51,12 milj. USD.

gaidāmā Beam Therapeutics peļņa ir -398,97 milj. USD.

Beam Therapeutics Inc is a leading company in the gene therapy industry, specializing in the development of advanced gene editing tools. The company is headquartered in Cambridge, Massachusetts and was founded in 2018. Its unique approach involves using precision gene editing to treat and cure genetic diseases and incurable conditions. Beam Therapeutics has established itself based on the revolutionary BEAM technology platform, which allows for the creation of gene editing tools with extremely high precision. BEAM stands for Base Editing by Advanced Machinery, and it is a type of gene editing that specifically alters individual building blocks in the genome instead of replacing the entire gene. This enables researchers at Beam Therapeutics to treat diseases in the genome with high precision and without size limitations. Beam Therapeutics Inc offers its technology platform in various business areas. The company's core area of focus is the development of the groundbreaking BEAM technology platform, which serves as the foundation for the development of a variety of gene correction tools. These tools enable researchers to target and treat diseases in the genome through precision gene editing. Additionally, Beam Therapeutics Inc also offers the development of gene therapies for specific diseases. For example, the company is working on editing gene sequences associated with cancer, sickle cell anemia, and beta-thalassemia. In collaboration with development partners, gene therapies are being developed and tested to determine the most effective treatment for these conditions. Another business area is the provision of services. Beam Therapeutics Inc offers technical services to its customers, such as genetic screenings. It is also possible to develop custom genome editing tools for research purposes or internal use. Beam Therapeutics Inc has a strong network of partnerships and has entered into agreements with various companies and institutions. The goal of these collaborations is to develop new gene therapies and conduct clinical trials. Furthermore, Beam Therapeutics Inc aims to connect researchers and scientists from around the world to advance developments in gene editing. In conclusion, Beam Therapeutics Inc specializes in the development and commercialization of precision gene editing tools and gene therapies for the treatment of genetic diseases and incurable conditions. The company operates in various business areas and offers unique and innovative solutions to researchers, developers, and customers through its BEAM technology platform.

Beam Therapeutics izmaksā dividendes 0 USD, kas tiek izmaksātas reizes gadā.

Dividendes pašlaik nevar aprēķināt Beam Therapeutics vai uzņēmums nedod dividendes.

Beam Therapeutics ISIN ir US07373V1052.

Beam Therapeutics WKN ir A2PY7P.

Beam Therapeutics simbols ir BEAM.

Pēdējo 12 mēnešu laikā Beam Therapeutics maksāja dividendes apmērā. Tas atbilst aptuveni dividendes ražībai. Nākamajos 12 mēnešos Beam Therapeutics plāno maksāt dividendes 0 USD apmērā.

Beam Therapeutics pašreizējā dividendu rentabilitāte ir .

Beam Therapeutics maksā dividendes ceturksnī. Tās tiek izmaksātas mēnešos decembris, marts, jūnijs, marts.

Beam Therapeutics pēdējo 0 gadu laikā katru gadu izmaksāja dividendes.

Nākamajiem 12 mēnešiem tiek prognozētas dividendes apmērā 0 USD. Tas atbilst dividendes ražībai 0 %.

Beam Therapeutics tiek piešķirts nozarei "Veselība".

Lai saņemtu pēdējo dividendu Beam Therapeutics apmērā 0,225 USD, kas tika izmaksāta 3.03.2014., tev akcija bija jāpatur depozītā līdz Ekss dienai, kas bija 4.02.2014..

Pēdējās dividendes izmaksa notika 3.03.2014..

Gadā 2023, Beam Therapeutics izmaksāja 0 USD dividendes.

Beam Therapeutics dividendes tiek izmaksātas USD.